Journal
CELL REPORTS
Volume 28, Issue 1, Pages 132-+Publisher
CELL PRESS
DOI: 10.1016/j.celrep.2019.05.109
Keywords
-
Categories
Funding
- NIH [R01CA181308]
- Mary Kay Foundation [045-15]
- Rivkin Center for Ovarian Cancer [567612, T32CA009515, R44CA221426, CA077852, CA193649, 174261]
Ask authors/readers for more resources
High-accuracy next-generation DNA sequencing promises a paradigm shift in early cancer detection by enabling the identification of mutant cancer molecules in minimally invasive body fluid samples. We demonstrate 80% sensitivity for ovarian cancer detection using ultra-accurate Duplex Sequencing to identify TP53 mutations in uterine lavage. However, in addition to tumor DNA, we also detect low-frequency TP53 mutations in nearly all lavages from women with and without cancer. These mutations increase with age and share the selection traits of clonal TP53 mutations commonly found in human tumors. We show that low-frequency TP53 mutations exist in multiple healthy tissues, from newborn to centenarian, and progressively increase in abundance and pathogenicity with older age across tissue types. Our results illustrate that subclonal cancer evolutionary processes are a ubiquitous part of normal human aging, and great care must be taken to distinguish tumor-derived from age-associated mutations in high-sensitivity clinical cancer diagnostics.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available